The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/ sulfamethoxazole: A single-center experience

Acta Haematologica

Volumn 127, Issue 2, 2012, Pages 110-114

  Hardak, Emilia ^a   Oren, Ilana ^b,d   Dann, Eldad J ^c,d   Yigla, Mordechai ^a,d   Faibish, Tal ^c   Rowe, Jacob M ^c,d   Avivi, Irit ^c,d  

^a Division of Pulmonary Medicine   (Israel)

^b Unit of Infectious Diseases   (Israel)

^c Rambam Health Care Campus ^*  (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Non Hodgkin lymphoma; Pneumocystis pneumonia; Prophylaxis; Rituximab CHOP regimens

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PREDNISONE; RETROSPECTIVE STUDIES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VINCRISTINE;

EID: 83455250642     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000334113     Document Type: Article

References (23)

1. Barbounis V, Aperis G, Gambletsas E, Koumakis G, Demiris M, Vassilomanolakis M, Efremidis A: Pneumocystis carinii pneumonia in patients with solid tumors and lymphomas: predisposing factors and outcome. Anticancer Res 2005; 25: 651-655. (Pubitemid 40470077)
2. Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P, Mitra ME, Picardi M, Caramatti C, Piccaluga P, Nosari A, Buelli M, Allione B, Cortelezzi A, Fabbiano F, Milone G, Invernizzi R, Martino B, Masini L, Todeschini G, Cappucci MA, Russo D, Corvatta L, Martino P, Del Favero A: Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002; 117: 379-386. (Pubitemid 34451154)
3. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS: High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010; 51: 797-801.
4. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006. (Pubitemid 23095683)
5. Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W, Lowenberg B: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530-2539.
6. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242. (Pubitemid 34438862)
7. Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, Fava S, Rigacci L, Pagnucco G, Pascutto C, Morra E, Lazzarino M: Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006; 91: 496-502.
8. Kolstad A, Holte H, Fossa A, Lauritzsen GF, Gaustad P, Torfoss D: Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOP-14 regimen. Haematologica 2007; 92: 139-140. (Pubitemid 46232678)
9. Oren I, Hardak E, Finkelstein R, Yigla M, Sprecher H: Polymerase chain reactionbased detection of Pneumocystis jirovecii in bronchoalveolar lavage fluid for the diagnosis of pneumocystis pneumonia. Am J Med Sci 2011; 342: 182-185.
10. Evidence Based Emergency Medicine. http://ebem.org/nntcalculator.html (accessed September 20, 2011).
11. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M: Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ Bcell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
12. Delarue R, Tilly H, Salles G, Gisselbrecht C, Mounier N, Fournier M, Molina TJ, Bonmati C, Ghesquieres H, Blanc M, Germain D, Girard L, Haioun C, Bosly A: R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study. Blood 2009; 114: 406a.
13. Cunningham D, Smith P, Mouncey P, Qian W, Jack AS, Pocock C, Ardeshna K, Radford JA, Davies AJ, McMillan A, Linch MD: RCHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol 2011; 29: 8000a.
14. Venhuizen AC, Hustinx WN, van Houte AJ, Veth G, van der Griend R: Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. Eur J Haematol 2008; 80: 275-276. (Pubitemid 351253467)
15. Pfreundschuh M, Poeschel V, Haenel M, Schmitz N, Ho A. D, Reiser M, Loeffler M, Schubert J: Improved outcome of elderly patients with poor-prognosis diffuse large Bcell lymphoma (DLBCL) after dose-dense rituximab: results of the dense-R-CHOP-14 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) J Clin Oncol 2008; 26: 8508a.
16. Kelesidis T, Daikos G, Boumpas D, Tsiodras S: Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 2011; 15:e2-e16.
17. Teichmann LL, Woenckhaus M, Vogel C, Salzberger B, Scholmerich J, Fleck M: Fatal pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 1256-1257. (Pubitemid 352038242)
18. Katz T, Stroopinsky D, Rowe JM, Avivi I: Rituximab directly decreases T cell activation, both in vivo and in vitro. Blood 2010; 116: 3935a.
19. Hashimoto K, Kobayashi Y, Asakura Y, Mori M, Azuma T, Maruyama D, Kim SW, Watanabe T, Tobinai K: Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma 2010; 51: 1816-1821.
20. Tadmor T, McLaughlin P, Polliack A: A resurgence of pneumocystis in aggressive lymphoma treated with R-CHOP-14: The price of a dose-dense regimen? Leuk Lymphoma 2010; 51: 737-738.
21. Kelly MN, Shellito JE: Current understanding of pneumocystis immunology. Future Microbiol 2010; 5: 43-65.
22. Lindemulder S, Albano E: Successful intermittent prophylaxis with trimethoprim/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics 2007; 120: e47-e51. (Pubitemid 47036215)
23. Isidori A, Merli F, Angrilli F, Ferrara F, Alesiani F, Visani G: The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis. Leuk Lymphoma 2011; 52: 148-149.